What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?

touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of leading experts discuss the latest guidelines for identifying and treating patients with HER2+ colorectal cancer, as well as the efficacy and safety data for HER2-targeted agents and their impact on clinical practice.   The experts Dr Ian Chau, Royal Marsden Hospital, London, UK Dr Antonia Sepulveda, George Washington University, Washington, DC, USA Dr Silvia Marsoni, IFOM ETS, Milan, Italy This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant from Seagen Inc. and is jointly provided by USF Health and touchIME.  For further information please visit: https://touchoncologyime.org/latest-data-for-her2-targeted-therapies-in-crc/